Oregon Public Employees Retirement Fund increased its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 2.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,023 shares of the medical equipment provider’s stock after acquiring an additional 397 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in ABIOMED were worth $2,533,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the stock. DE Burlo Group Inc. bought a new position in shares of ABIOMED during the third quarter worth $2,849,000. American Century Companies Inc. lifted its position in ABIOMED by 99.8% during the third quarter. American Century Companies Inc. now owns 484,142 shares of the medical equipment provider’s stock valued at $81,626,000 after purchasing an additional 241,868 shares during the last quarter. State of Tennessee Treasury Department bought a new position in ABIOMED during the third quarter valued at $5,058,000. State of Wisconsin Investment Board lifted its position in ABIOMED by 3.6% during the third quarter. State of Wisconsin Investment Board now owns 8,364 shares of the medical equipment provider’s stock valued at $1,410,000 after purchasing an additional 294 shares during the last quarter. Finally, Chicago Equity Partners LLC bought a new position in ABIOMED during the third quarter valued at $263,000. Hedge funds and other institutional investors own 90.46% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Oregon Public Employees Retirement Fund Has $2.53 Million Stake in ABIOMED, Inc. (ABMD)” was first published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/11/13/oregon-public-employees-retirement-fund-has-2-53-million-stake-in-abiomed-inc-abmd.html.
Shares of ABIOMED, Inc. (NASDAQ ABMD) opened at $195.21 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84. ABIOMED, Inc. has a 12 month low of $103.53 and a 12 month high of $198.29. The company has a market cap of $8,631.43, a P/E ratio of 125.14, a price-to-earnings-growth ratio of 2.60 and a beta of 0.23.
ABIOMED (NASDAQ:ABMD) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.16. The firm had revenue of $132.80 million during the quarter, compared to analyst estimates of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The business’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.20 EPS. equities research analysts predict that ABIOMED, Inc. will post 2.38 earnings per share for the current year.
In other news, Director Eric A. Md Rose sold 982 shares of ABIOMED stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $145.17, for a total transaction of $142,556.94. Following the completion of the transaction, the director now directly owns 13,634 shares of the company’s stock, valued at approximately $1,979,247.78. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Dorothy E. Puhy sold 6,364 shares of ABIOMED stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the transaction, the director now directly owns 39,532 shares of the company’s stock, valued at $7,079,390.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,646 shares of company stock valued at $10,003,780. Insiders own 7.00% of the company’s stock.
Several equities research analysts have recently issued reports on ABMD shares. Jefferies Group LLC raised their target price on shares of ABIOMED from $165.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, August 4th. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, August 10th. SunTrust Banks, Inc. initiated coverage on shares of ABIOMED in a research note on Friday, September 29th. They issued a “buy” rating and a $195.00 price target on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $160.00 price target on shares of ABIOMED in a research note on Tuesday, August 29th. Finally, Zacks Investment Research raised shares of ABIOMED from a “sell” rating to a “buy” rating and set a $203.00 target price on the stock in a research report on Monday, October 30th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $185.38.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.